- Enabling Economic Recovery Through Innovation
- The Top 12 Science Progress Features of 2008
- Breaking: Physicist John Holdren Is Likely Pick for Science Advisor
- Looking for a Research Bailout
- Want to Work Together? The Impact of Multi-University Collabortion
- “The Single Most Effective Way to Prevent the Transmission of Disease”
- Chu Is Bringing Science Back
- National Research Council: Nanotech Safety Needs a Closer Look. Much Closer.
- Neuroscience Everywhere
- Change for America on Science and Tech Policy, Part 4: The Office of Science and Technology Policy
- CNN Decides It Can Cover Science Without Dedicated Science Reporters
- Stem Cell Recommendations for the New Administration
Snap Observations: China Cleans House at Drug Approval Agency
The efforts of China’s State Food and Drug Administration to crack down on drug and medical device companies seems to be improving the industry’s reputation and will hopefully make for a safer marketplace. As the country’s economy grows, regulation will have to keep pace.
Three hundred drug and medical instrument manufacturers have been shut down; pharmaceutical companies withdrew 7,300 applications for drug approval; and 1,100 previously approved drugs and medical appliances were found to have been approved illegally. Wu Zhen, deputy commissioner of the SFDA told a press conference that, “the pharmaceutical companies are examining themselves in this special campaign and their awareness for drug safety has been greatly enhanced.”
Internal corruption has also plagued the SFDA. Former director Zheng Xiaoyu was executed in July for taking some $850,000 in bribes during his tenure.
Comments on this article